Applied Energetics (AERG) 10-K 30 Mar 22 2021 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 18, 2022	Jun. 30, 2021
Document Information Line Items
Entity Registrant Name	APPLIED ENERGETICS, INC.
Trading Symbol	AERG
Document Type	10-K
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		207,692,878
Entity Public Float			$ 81,178,513
Amendment Flag	false
Entity Central Index Key	0000879911
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
ICFR Auditor Attestation Flag	false
Document Annual Report	true
Document Transition Report	false
Entity File Number	001-14015
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	77-0262908
Entity Address, Address Line One	9070 S. Rita Road
Entity Address, Address Line Two	Suite 1500
Entity Address, City or Town	Tucson
Entity Address, State or Province	AZ
Entity Address, Postal Zip Code	85747
City Area Code	(520)
Local Phone Number	628-7415
Title of 12(b) Security	Common Stock, $.001 par value
Security Exchange Name	NYSE
Entity Interactive Data Current	Yes
Auditor Name	RBSM LLP
Auditor Location	Las Vegas, NV
Auditor Firm ID	587

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 3,662,615	$ 3,323,290
Other receivable		2,880
Other assets	43,391	39,352
Total current assets	3,706,006	3,365,522
Long-term assets
Security deposit	17,004
Property and equipment - net	206,810	19,466
Deferred compensation	416,666	1,250,001
Right of Use Asset - Operating	544,670
Total Long-term assets	1,185,150	1,269,467
TOTAL ASSETS	4,891,156	4,634,989
Current liabilities
Accounts payable	195,381	152,445
Notes payable	1,000,000	1,547,695
Notes payable CARES Act PPP Loan	24,189
Due to related parties	50,000	50,000
Operating Lease Liability - current	76,227
Accrued expenses	21,870	938
Accrued dividends	48,079	48,079
Total current liabilities	1,415,747	1,799,157
Long-term liabilities Operating Lease Liability - non-current	507,188
Long-term notes payable		1,000,000
Long-term notes payable CARES Act PPP Loan		133,462
Total long-term liabilities	507,188	1,133,462
Total liabilities	1,922,935	2,932,619
Stockholders’ equity
Series A convertible preferred stock, $.001 par value, 2,000,000 shares authorized and 13,602 shares issued and outstanding at December 31, 2021 and at December 31, 2020 (Liquidation preference $340,050 and $340,050, respectively)	14	14
Common stock, $.001 par value, 500,000,000 shares authorized; 207,562,461 and 190,529,320 shares issued and outstanding at December 31, 2021 and at December 31, 2020, respectively	207,562	190,529
Additional paid-in capital	100,452,862	93,778,591
Accumulated deficit	(97,692,217)	(92,266,764)
Total stockholders’ equity	2,968,221	1,702,370
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 4,891,156	$ 4,634,989

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Series A convertible preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Series A convertible preferred stock, authorized	2,000,000	2,000,000
Series A convertible preferred stock, issued	13,602	13,602
Series A convertible preferred stock, outstanding	13,602	13,602
Series A convertible preferred stock, liquidation preference (in Dollars)	$ 340,050	$ 340,050
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	207,562,461	190,529,320
Common stock, shares outstanding	207,562,461	190,529,320

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Revenue		$ 175,920
Cost of revenue		(153,630)
Gross profit		22,290
Operating expenses:
General and administrative	4,903,081	4,698,624
Selling and marketing	317,350	296,461
Research and development	281,896	266,864
Total operating expenses	5,502,327	5,261,949
Operating loss	(5,502,327)	(5,239,659)
Other income/(expense)
Other income	81,218	15,832
Gain on settlement		3,206,000
Interest expense	(4,344)	(1,212,667)
Total other income/(expense)	76,874	2,009,165
Loss before provision for income taxes	(5,425,453)	(3,230,494)
Provision for income taxes
Net loss	(5,425,453)	(3,230,494)
Preferred stock dividends	(34,005)	(34,005)
Net loss attributable to common stockholders	$ (5,459,458)	$ (3,264,499)
Net loss attributable to common stockholders per common share – basic and diluted (in Dollars per share)	$ (0.03)	$ (0.02)
Weighted average number of common shares outstanding, basic and diluted (in Shares)	200,854,103	193,505,618

Consolidated Statements of Stoc

Consolidated Statements of Stockholders’ Equity - USD ($)	Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2019	$ 14	$ 206,569	$ 85,907,523	$ (89,036,271)	$ (2,922,165)
Balance (in Shares) at Dec. 31, 2019	13,602	206,569,062
Stock-based compensation expense			1,487,701		1,487,701
Restricted stock agreement-based non-cash compensation		$ 19	13,106		13,125
Restricted stock agreement-based non-cash compensation (in Shares)		18,750
Common stock issued on exercise of stock option and warrant		$ 1,075	74,175		75,250
Common stock issued on exercise of stock option and warrant (in Shares)		1,075,000
Sale of common stock		$ 5,480	1,638,620		1,644,100
Sale of common stock (in Shares)		5,480,334
Cancellation of common stock		$ (11,000)	11,000
Cancellation of common stock (in Shares)		(11,000,000)
Accrual of payment in anticipation of settlement		$ (25,000)	(1,475,000)		(1,500,000)
Accrual of payment in anticipation of settlement (in Shares)		(25,000,000)
Stock issuance to pay off convertible notes and accrued interest		$ 18,386	5,497,466		5,515,852
Stock issuance to pay off convertible notes and accrued interest (in Shares)		18,386,174
Purchase and cancellation of common stock		$ (5,000)	(295,000)		300,000
Purchase and cancellation of common stock (in Shares)		(5,000,000)
Recognize beneficial conversion feature			919,000		919,000
Net loss for the year ended				(3,230,494)	(3,230,494)
Balance at Dec. 31, 2020	$ 14	$ 190,529	93,778,591	(92,266,764)	1,702,369
Balance (in Shares) at Dec. 31, 2020	13,602	190,529,320
RSU restricted stock		$ 31	4,519		4,550
RSU restricted stock (in Shares)		31,250
Stock-based compensation			1,232,256		1,232,256
Common stock issued on cashless exercise of options and warrants		$ 4,084	(4,084)
Common stock issued on cashless exercise of options and warrants (in Shares)		4,082,637
Common stock issued on exercise of options and warrants		$ 1,650	106,350		108,000
Common stock issued on exercise of options and warrants (in Shares)		1,650,010
Common stock issued on exercised of convertible note		$ 158	47,340		47,498
Common stock issued on exercised of convertible note (in Shares)		158,329
Sale of common stock		$ 11,110	5,287,890		5,299,000
Sale of common stock (in Shares)		11,110,915
Net loss for the year ended				(5,425,453)	(5,425,453)
Balance at Dec. 31, 2021	$ 14	$ 207,562	$ 100,452,862	$ (97,692,217)	$ 2,968,221
Balance (in Shares) at Dec. 31, 2021	13,602	207,562,461

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (5,425,453)	$ (3,230,494)
Adjustments to reconcile net loss to net cash used in operating activities:
Noncash stock based compensation expense	1,236,806	1,500,825
Gain on settlement of accrued compensation		(206,000)
Common Stock issued for interest expenses		229,296
Amortization of beneficial conversion feature		919,000
Depreciation and amortization	20,024	17,102
PPP loan forgiveness	(81,550)
Amortization of future compensation payable	833,333	833,333
Amortization of prepaid assets	156,562	149,856
Changes in assets and liabilities:
Accounts receivable		9,888
Other receivable	2,880
Inventory		5,930
Prepaids and deposits	(60,395)	(44,275)
ROU liabilities	38,745
Accounts payable	42,936	(232,341)
Accrued interest	1,386	(89,755)
Accrued expenses and compensation	20,932	(22,649)
Net cash used in operating activities	(3,213,794)	(160,284)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of equipment	(207,367)
Net cash used by investing activities	(207,367)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sale of common stock	5,299,000	1,644,100
Purchase and cancellation of stock		(1,300,000)
Repayment of insurance premium loan		(108,064)
Repayment on note payable	(1,646,513)	(1,372,887)
Proceeds from note payable		4,324,000
Proceeds from SBA loan		132,760
Proceeds from the exercise of stock options and warrants	108,000	75,250
Net cash provided by financing activities	3,760,487	3,395,159
Net increase in cash and cash equivalents	339,325	3,234,875
Cash and cash equivalents, beginning of year	3,323,290	88,415
Cash and cash equivalents, end of year	3,662,615	3,323,290
Supplemental Cash Flow Information
Cash paid for interest	1,421	53,976
Cash paid for taxes
Schedule of Non-Cash Information
Insurance financing for prepaid insurance	117,209	108,064
Implementation of ASC 842	617,569
Forgiveness of PPP loan	81,550
Equipment investing in accounts payable	64,107
Common stock issued for repayment of convertible notes	47,498	5,253,614
Beneficial conversion feature on notes payable		919,000
Long term investment utilized for cancellation of shares		$ 500,000

Organization of Business, Going

Organization of Business, Going Concern and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
ORGANIZATION OF BUSINESS, GOING CONCERN AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 - ORGANIZATION OF BUSINESS, GOING CONCERN AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The consolidated financial statements include the accounts of Applied Energetics, Inc. and its wholly owned subsidiary North Star Power Engineering, Inc. (“North Star”) (collectively, “company,” “Applied Energetics,” “AERG”, “we,” “our” or “us”). All intercompany balances and transactions have been eliminated. Going Concern The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. For the year ended December 31, 2021, the company incurred a net loss of approximately $5,425,000, had negative cash flows from operations of approximately $3,214,000 and may incur additional future losses due to the reduction in Government contract activity. At December 31, 2021, the company had total current assets of approximately $3,706,000 and total current liabilities of approximately $1,416,000 resulting in working capital of approximately $2,290,000. At December 31, 2021, the company had cash of approximately $3,663,000. As of December 31, 2021, the company had cash of approximately $3,663,000. Based on the company’s current business plan, it believes its cash balance as of the date of this filing will be sufficient to meet its anticipated cash requirements for the next twelve months. However, there can be no assurance that the current business plan will be achievable. Such conditions raise substantial doubts about the company’s ability to continue as a going concern for one year from the date the financial statements are issued. The company’s existence is dependent upon management’s ability to develop profitable operations. Management is devoting substantially all of its efforts to developing its business and raising capital and there can be no assurance that the company’s efforts will be successful. No assurance can be given that management’s actions will result in profitable operations or the resolution of its liquidity problems. The accompanying consolidated financial statements do not include any adjustments that might result should the company be unable to continue as a going concern. The ongoing COVID-19 pandemic contributes to this uncertainty. In order to improve the company’s liquidity, the company’s management is actively pursuing additional equity financing through discussions with investment bankers and private investors. There can be no assurance that the company will be successful in its effort to secure additional equity financing. The financial statements do not include any adjustments relating to the recoverability of assets and the amount or classification of liabilities that might be necessary should the company be unable to continue as a going concern. Applied Energetics, Inc. is a corporation organized and existing under the laws of the State of Delaware. Our executive office and laboratory space are located at 9070 S. Rita Road, Suite 1500, Tucson, Arizona, 85747, and our telephone number is (520) 628-7415. Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and accompanying notes. Management bases its assumptions on historical experiences and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. In addition, management considers the basis and methodology used in developing and selecting these estimates, the trends in and amounts of these estimates, specific matters affecting the amount of and changes in these estimates, and any other relevant matters related to these estimates, including significant issues concerning accounting principles and financial statement presentation. Such estimates and assumptions could change in the future as more information becomes known which could impact the amounts reported and disclosed herein. Significant estimates include revenue recognition, carrying amounts of long-lived assets, valuation assumptions for share-based payments, evaluation of debt modification accounting, effective borrowing rate determinations, analysis of fair value transferred upon debt extinguishment, valuation and calculation of measurements of income tax assets and liabilities and valuation of debt discount related to beneficial conversion features. Net Loss Attributable to Common Stockholders Basic loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period before giving effect to stock options, stock warrants, restricted stock units and convertible securities outstanding, which are considered to be dilutive common stock equivalents. Diluted net loss per common share is calculated based on the weighted average number of common and potentially dilutive shares outstanding during the period after giving effect to dilutive common stock equivalents. Contingently issuable shares are included in the computation of basic loss per share when issuance of the shares is no longer contingent. The number of warrants, options, restricted stock units and our Series A Convertible Preferred Stock, which were not included in the computation of earnings per share because the effect was antidilutive, was 30,343,602 and 35,612,091 for the years ended December 31, 2021 and 2020, respectively. Fair Value of Current Assets and Liabilities The carrying amount of accounts payable approximate fair value due to the short maturity of these instruments. Cash and Cash Equivalents Cash equivalents are investments in money market funds or securities with an initial maturity of three months or less. We maintain our cash balances at a commercial bank, and, at times, balances exceed FDIC limits. As of December 31, 2021, $3,412,615 of our cash balance was uninsured. Income Taxes Deferred tax assets and liabilities are recognized currently for the future tax consequences attributable to the temporary differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets if it is more likely than not that such assets will not be realized. Our valuation allowance is currently 100% of our assets. We consider all available evidence, both positive and negative, to determine whether, based on the weight of that evidence, a valuation allowance is needed for some portion or all of a net deferred tax asset. Judgment is used in considering the relative impact of negative and positive evidence. In arriving at these judgments, the weight given to the potential effect of negative and positive evidence is commensurate with the extent to which it can be objectively verified. We record a valuation allowance to reduce our deferred tax assets and review the amount of such allowance annually. When we determine certain deferred tax assets are more likely than not to be utilized, we will reduce our valuation allowance accordingly. Revenue Recognition The company recognizes revenue in accordance with ASC Topic 606 – Revenue from Contracts with Customers (“ASC 606”) to depict the transfer of control to the company’s customers in an amount reflecting the consideration the company expects to be entitled. The company determines revenue recognition through the following steps: i. Identification of the contract, or contracts, with a customer ii. Identification of the performance obligations in the contract iii. Determination of the transaction price iv. Allocation of the transaction price to the performance obligations in the contract v. Recognition of revenue, when, or as, the company satisfied the performance obligation The company generated revenue from its customer by preparing a technical report. The company’s single performance obligation was to deliver the final technical report detailing the findings of the company’s investigations. The fee for the report was fixed. Share-Based Payments Employee stock-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period. The fair value of each option grant is estimated at the date of grant using the Black-Scholes-Merton option valuation model. We make the following assumptions relative to this model: (i) the annual dividend yield is zero as we do not pay dividends on common stock, (ii) the weighted-average expected life is based on a midpoint scenario, where the expected life is determined to be half of the time from grant to expiration, regardless of vesting, (iii) the risk free interest rate is based on the U.S. Treasury security rate for the expected life, and (iv) the volatility is based on the level of fluctuations in our historical share price for a period equal to the weighted-average expected life. We estimate forfeitures when recognizing compensation expense and adjust this estimate over the requisite service period should actual forfeitures differ from such estimates. Changes in estimated forfeitures are recognized through a cumulative adjustment, which is recognized in the period of change, and which impacts the amount of unamortized compensation expense to be recognized in future periods. Significant Concentrations and Risks We maintain cash balances at a commercial bank, and, at times, balances exceed FDIC limits. As of December 31, 2021, $3,412,615 of our cash balance was uninsured.

New Accounting Standards

New Accounting Standards	12 Months Ended
	Dec. 31, 2021
Accounting Standards Update and Change in Accounting Principle [Abstract]
NEW ACCOUNTING STANDARDS	NOTE 2 – NEW ACCOUNTING STANDARDS The company has reviewed all issued accounting pronouncements and plans to adopt those that are applicable to it. The company does not expect the adoption of any other pronouncements to have an impact on its results of operations or financial position. In December 2019, the FASB issued amended guidance in the form of ASU No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.” This ASU is intended to simplify various aspects related to accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying certain aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective for annual periods beginning after December 15, 2020, and interim periods within those annual periods, with early adoption permitted. An entity that elects early adoption must adopt all the amendments in the same period. Most amendments within this ASU are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. The company has evaluated the impact of this new standard and notes the guidance will not have a material impact on our financial statements. On August 5, 2020, the FASB issued ASU No. 2020-06 which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. ASU 2020-06 simplifies the guidance in U.S. GAAP on the issuer’s accounting for convertible debt instruments. Such guidance includes multiple disparate sets of classification, measurement, and derecognition requirements whose interactions are complex. ASU 2020-06 is effective for annual periods beginning after December 15, 2021, and interim periods within those annual periods, with early adoption permitted. An entity that elects early adoption must adopt all the amendments in the same period. Most amendments within this ASU are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. The company is in the initial stage of evaluating the impact of this new standard however it does not believe the guidance will have a material impact on our financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). This standard requires all leases that have a term of over 12 months to be recognized on the balance sheet with the liability for lease payments and the corresponding right-of-use asset initially measured at the present value of amounts expected to be paid over the term. Recognition of the costs of these leases on the income statement will be dependent upon their classification as either an operating or a financing lease. Costs of an operating lease will continue to be recognized as a single operating expense on a straight-line basis over the lease term. Costs for a financing lease will be disaggregated and recognized as both an operating expense (for the amortization of the right-of-use asset) and interest expense (for interest on the lease liability). The company has adopted this standard beginning July 1, 2020, and the company now applies it on a modified retrospective basis to leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. For the year ended December 31, 2021, the company had one lease to which the standard applies. The adoption of the new standard resulted in the recognition of a right-of-use asset and lease liability of $617,569 and $617,569, respectively. At December 31, 2021, the right-of-use asset and lease liability were valued at $544,670 and $583,415, respectively

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTE 3 – NOTES PAYABLE On May 24, 2019, the company entered into an Asset Purchase Agreement (the “APA”) with Applied Optical Sciences, LLC (“AOS”) to acquire certain assets. As consideration for the APA, the company entered into a promissory note issued to the shareholders of AOS for $2,500,000. The note is non-interest bearing and shall be repaid in equal installments. The company made the first three payments of $500,000 on February 10, 2021, May 24, 2021, and November 19, 2021, respectively. In accordance with the terms of the note, $500,000 is due on May 24, 2022 and the remaining $500,000 is due on November 24, 2022. The Promissory Note may be prepaid at any time (in whole or in part). Upon inception, the company recorded a debt discount in the amount of $2,500,000 in relation to the transaction which is being amortized over the life of the loan as compensation expense. During the year ended December 31, 2021, the company made payments in the amount of $1,500,000, in the aggregate, for this promissory note. As of December 31, 2021, and December 31, 2020, the note is not in default. Paycheck Protection Program On April 28, 2020, the company entered into a loan agreement with Alliance Bank of Arizona, N.A. for a loan in the amount of $132,760 pursuant to the Paycheck Protection Program (the “PPP”) under the Coronavirus Aid, Relief, and Economic Security Act enacted on March 27, 2020 (the “CARES Act”). This loan is evidenced by a promissory note dated April 27, 2020, and matures two years from the disbursement date. This loan bears interest at a rate of 1.00% per annum, with the first nine months of interest deferred. Principal and interest are payable monthly commencing nine months after the disbursement date and may be prepaid by the company at any time prior to maturity with no prepayment penalties. This loan contains customary events of default relating to, among other things, payment defaults or breaches of the terms of the loan. Upon the occurrence of an event of default, the lender may require immediate repayment of all amounts outstanding under the note. Under the terms of the PPP, up to the entire amount of principal and accrued interest may be forgiven to the extent loan proceeds are used for qualifying expenses as described in the CARES Act and applicable implementing guidance issued by the U.S. Small Business Administration (“SBA”) under the PPP. The company partially used the loan amount for designated qualifying expenses and received notice from the SBA on June 30, 2021, that the company would not be required to repay $81,550 in proceeds. As a result, the company received partial forgiveness of the PPP amounting to $80,594 in principal and $956 in interest which is reflected within PPP forgiveness and other income on the statements of operations. Additionally, the company made five payments during the year ended December 31, 2021, for a total of $29,306. As of December 31, 2021, $22,804 in principal and $1,385 in interest were outstanding and continue to accrue interest at 1% per annum. The loan is due to be repaid on April 20, 2022. Premium Financing On March 25, 2021, the company entered into an agreement with Oakwood D&O Insurance to provide financing in an amount of $156,279 for the insurance premium associated with two D&O policies. Both policies commenced March 12, 2021, and provided coverage for the next 12 months, expiring March 12, 2022. The loan bears interest at a fixed rate of 6.5% per annum and required the company to prepay $39,070 during the last three months of the term. On April 12, 2021, the company commenced monthly principal and interest payments of $13,024 on the remaining nine months due of $117,209, for the remaining nine months. The last payment was made on December 31, 2021. As of December 31, 2021, the outstanding balance on the note was $0. During the year ended December 31, 2021, the company converted $47,498 of notes payable into 158,329 shares of common stock. The following reconciles notes payable as of December 31, 2021 and December 31, 2020: December 31, December 31, Beginning balance $ 2,681,157 $ 4,967,890 Notes payable 117,209 4,456,760 Accrued interest 1,385 297,849 Transfer from prepaid - 108,064 Initial beneficial conversion feature - (919,000 ) Amortize beneficial conversion feature - 919,000 Payments on notes payable (1,646,513 ) (1,480,951 ) Repayment of interest - (152,603 ) Extinguishment of Debt (81,550 ) - Converted into common stock (47,498 ) (5,515,852 ) Total 1,024,190 2,681,157 Less-Notes payable - current 1,024,190 (1,547,695 ) Notes payable - non-current $ - $ 1,133,462 Future principal payments for the company’s Notes as of December 31, 2021 are as follows: 2022 $ 1,024,190 Thereafter - Total $ 1,024,190 The company’s note payable balance of $1,204,190 is due within the next twelve months, in accordance with the terms of note payable. Of the remaining $1,204,190, $1,000,000 consists of two remaining payments of $500,000, due on May 24, 2022 and November 24, 2022, which is the remaining balance on the note payable that the company assumed as part of the agreement to acquire Applied Optical Sciences. In accordance with the terms of note payable, the company made the first three payments of $500,000 on February 10, 2021, May 24, 2021, and November 19, 2021. Subsequent to the year ended December 31, 2021, the company entered into a $175,434.65 financing agreement to finance its Directors and Officers insurance premiums.

Deferred Compensation

Deferred Compensation	12 Months Ended
	Dec. 31, 2021
Deferred Compensation [Abstract]
DEFERRED COMPENSATION	NOTE 4 – DEFERRED COMPENSATION On May 24, 2019, the company entered into the APA with AOS to acquire certain assets. As consideration for the APA, the company entered into a promissory note issued to the shareholders of AOS for $2,500,000. The company also recorded a debt discount, which is reported on the balance sheet as deferred compensation, in the amount of $2,500,000 in relation to the transaction which is being amortized over the life of the loan as compensation expense. The amortization of deferred compensation for the year ended December 31, 2021, and 2020 was $833,333 and $833,333, respectively. As of December 31, 2021, and 2020, the remaining deferred compensation to be amortized was $416,667 and $1,250,000, respectively.

Due to Related Parties

Due to Related Parties	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
DUE TO RELATED PARTIES	NOTE 5 – DUE TO RELATED PARTIES It has come to the board’s attention that on July 31, 2018, our now deceased CEO deposited $50,000 into the company’s account. Although it has been suggested that the funds may have been intended for use toward Mr. Dearmin’s healthcare, the board does not know for certain what the purpose of the funds were or the nature of any intended investment. Accordingly, the board is investigating the appropriate disposition of the funds which will likely be to the estate of Mr. Dearmin. Until such a determination is made, the board does not intend to use these funds for any corporate purpose. For reporting purposes, the company has treated the deposit as a due to related party.

Stockholders_ Deficit

Stockholders’ Deficit	12 Months Ended
	Dec. 31, 2021
Stockholders' Equity Note [Abstract]
STOCKHOLDERS’ DEFICIT	NOTE 6 – STOCKHOLDERS’ DEFICIT Authorized Capital Stock The company’s authorized capital stock consists of 500,000,000 shares of common stock at a par value of $.001 per share and 2,000,000 shares of preferred stock at a par value of $.001 per share. In January 2020, the company received $603,000 from five non-affiliated individuals based on subscription agreements with the company for which the company issued 2,010,000 shares of its common stock. In January 2020, the company issued 25,000 shares upon exercise of a warrant by a non-affiliated warrant holder at an exercise price of $0.07 per share. In February 2020, the company received $510,000 from a non-affiliated individual based on a subscription agreement with the company for which the company issued 1,700,000 shares of its common stock. In April 2020, the company received $11,000 from an individual based on a warrant exercise for which the company issued 150,000 shares of its common stock. In April 2020, the company received $63,000 from an individual based on an option exercise for which the company issued 900,000 shares of its common stock. In April 2020, the company received $531,000, in the aggregate, from an individuals based on subscription agreements with the company for which the company issued 1,770,333 shares of its common stock. During the year ended December 31, 2021, the company issued 4,054,665 shares of common stock in a private placement to accredited investors for $0.75 per share or $3,041,000 of net cash proceeds, in the aggregate. During the year ended December 31, 2021, the company issued 7,056,250 shares of common stock in a private placement to accredited investors for $0.32 per share or $2,258,000 of net cash proceeds, in the aggregate. During the year ended December 31, 2021, the company issued 158,329 shares of common stock upon the conversion of $47,498 of convertible notes (see Note 3). During the year ended December 31, 2021, the company issued 31,250 shares of common stock in relation to a restricted stock agreement with a value of $4,550. During the year ended December 31, 2021, the company issued 800,000 shares of common stock upon the exercise of 800,000 warrants at an exercise price of $0.07 a share. During the year ended December 31, 2021, the company issued 250,000 shares of common stock upon the exercise of 250,000 warrants at an exercise price of $0.06 a share. During the year ended December 31, 2021, the company issued 50,000 shares of common stock upon the exercise of 50,000 warrants at an exercise price of $0.06 a share. During the year ended December 31, 2021, the company issued 100,000 shares of common stock upon the exercise of 100,000 warrants at an exercise price of $0.07 a share. During the year ended December 31, 2021, the company issued 200,000 shares of common stock upon the exercise of 200,000 warrants at an exercise price of $0.06 a share. During the year ended December 31, 2021, the company issued 125,000 shares of common stock upon the exercise of 125,000 warrants at an exercise price of $0.06 a share. During the year ended December 31, 2021, the company issued 60,000 shares of common stock upon the exercise of 60,000 warrants at an exercise price of $0.06 a share. During the year ended December 31, 2021, the company issued 65,000 shares of common stock upon the exercise of 65,000 warrants at an exercise price of $0.06 a share. During the year ended December 31, 2021, the company issued 1,005,682 shares of common stock upon the exercise of 1,090,910 options at an exercise price of $0.05 a share. This exercise was performed on a cashless basis. During the year ended December 31, 2021, the company issued 259,741 shares of common stock upon the exercise of 500,000 options at an exercise price of $0.37 a share. This exercise was performed on a cashless basis. During the year ended December 31, 2021, the company issued 475,000 shares of common stock with an exercise of 500,000 options. 25,000 shares of common stock were withheld with the exercise. This exercise was performed on a cashless basis. During the year ended December 31, 2021, the company issued 482,143 shares of common stock with an exercise of 500,000 options. 17,857 shares of common stock were withheld with the exercise. This exercise was performed on a cashless basis. During the year ended December 31, 2021, the company issued 728,814 shares of common stock with an exercise of 750,000 options. 21,186 shares of common stock were withheld with the exercise. This exercise was performed on a cashless basis. During the year ended December 31, 2021, the company issued 400,158 shares of common stock with an exercise of 409,090 options. 8,932 shares of common stock were withheld with the exercise. This exercise was performed on a cashless basis. During the year ended December 31, 2021, the company issued 731,109 shares of common stock with an exercise of 750,000 options. 18,891 shares of common stock were withheld with the exercise. This exercise was performed on a cashless basis. During the year ended December 31, 2021, the company recognized stock-based compensation in the amount of $1,236,806. Preferred Stock As of December 31, 2021, and 2020 there were 13,602 and 13,602 shares of Series A Redeemable Convertible Preferred Stock (the “Series A Preferred Stock”) outstanding, respectively. The company has not paid the dividends commencing with the quarterly dividend due August 1, 2013. Dividend arrearages as of December 31, 2021, including previously accrued dividends included in our balance sheet are approximately $295,000. Our Board of Directors suspended the declaration of the dividend, commencing with the dividend payable as of February 1, 2015, since we did not have a surplus (as such term is defined in the Delaware general corporation Law) as of December 31, 2014, until such time as we have a surplus or net profits for a fiscal year. Our Series A Preferred Stock has a liquidation preference of $25.00 per Share. The Series A Preferred Stock bears dividends at the rate of 6.5% of the liquidation preference per share per annum, which accrues from the date of issuance, and is payable quarterly. Dividends may be paid in: (i) cash, (ii) shares of our common stock (valued for such purpose at 95% of the weighted average of the last sales prices of our common stock for each of the trading days in the ten trading day period ending on the third trading day prior to the applicable dividend payment date), provided that the issuance and/or resale of all such shares of our common stock are then covered by an effective registration statement and the company’s common stock is listed on a U.S. national securities exchange or the Nasdaq Stock Market at the time of issuance or (iii) any combination of the foregoing. If the company fails to make a dividend payment within five business days following a dividend payment date, the dividend rate shall immediately and automatically increase by 1% from 6.5% of the liquidation preference per offered share of Series A preferred stock to 7.5% of such liquidation preference. If a payment default shall occur on two consecutive dividend payment dates, the dividend rate shall immediately and automatically increase to 10% of the liquidation preference for as long as such payment default continues and shall immediately and automatically return to the Initial dividend rate at such time as the payment default is no longer continuing. Each share of Series A Preferred Stock is convertible at any time at the option of the holder into a number of shares of common stock equal to the liquidation preference (plus any unpaid dividends for periods prior to the dividend payment date immediately preceding the date of conversion by the holder) divided by the conversion price (initially $12.00 per share, subject to adjustment in the event of a stock dividend or split, reorganization, recapitalization or similar event.) If the closing sale price of the common stock is greater than 140% of the conversion price on 20 out of 30 trading days, the company may redeem the Series A Preferred Stock in whole or in part at any time through October 31, 2010, upon at least 30 days’ notice, at a redemption price, payable in cash, equal to 100% of the liquidation preference of the shares to be redeemed, plus unpaid dividends thereon to, but excluding, the redemption date, subject to certain conditions. In addition, beginning November 1, 2010, the company may redeem the Series A Preferred Stock in whole or in part, upon at least 30 days’ notice, at a redemption price, payable in cash, equal to 100% of the liquidation preference of the Series A Preferred Stock to be redeemed, plus unpaid dividends thereon to, but excluding, the redemption date, under certain conditions. If a change of control occurs, each holder of shares of Series A Convertible Preferred Stock that are outstanding immediately prior to the change of control shall have the right to require the corporation to purchase, out of legally available funds, any outstanding shares of Series A Convertible Preferred Stock at the defined purchase price. The purchase price is defined as: per share of Preferred Stock, 101% of the liquidation preference thereof, plus all unpaid and accumulated dividends, if any, to the date of purchase thereof. The purchase price is payable, at the corporation’s option, (x) in cash, (y) in shares of the common stock at a discount of 5% from the fair market value of Common Stock on the Purchase Date (i.e. valued at a 95% discount of the Common Stock on the Purchase Date), or (z) any combination thereof. If the Corporation pays all or a portion of the Purchase Price in Common Stock, no fractional shares of Common Stock will be issued; instead, the company will round the applicable number of shares of Common Stock up to the nearest whole number of shares; provided that the Corporation may pay the Purchase Price (or a portion thereof), whether in cash or in shares of Common Stock, only if the Corporation has funds legally available for such payment and may pay the Purchase Price (or a portion thereof) in shares of its Common Stock only if (i) the Common Stock is listed on a U.S. national securities exchange or the Nasdaq Stock Market at the time of issuance and (ii) a shelf registration statement covering the issuance by the Corporation and/or resales of the Common Stock issuable as payment of the Purchase Price is effective on the Payment Date unless such shares are eligible for immediate resale in the public market by non-affiliates of the Corporation. Dividends on our Preferred Stock are payable quarterly on the first day of February, May, August and November, in cash or shares of Common Stock, at our discretion. Share-Based Payments Effective November 12, 2018, the Board of Directors of Applied Energetics, Inc. adopted the 2018 Incentive Stock Plan. The plan provides for the allocation and issuance of stock, restricted stock purchase offers and options (both incentive stock options and non-qualified stock options) to officers, directors, employees and consultants of the company. The board reserved a total of 50,000,000 shares for possible issuance under the plan. We have, from time to time, also granted non-plan options to certain officers, directors, employees and consultants. Total stock-based compensation expense for grants to officers, employees and consultants was $1,232,256 and $1,501,000 for the year ended December 31, 2021, and 2020, respectively, which was charged to general and administrative expense. The $1,236,806 stock-based compensation for the year ended December 31, 2021, was comprised of $520,819 option expense and $669,000 was the amortization of 5,000,000 shares of stock valued at $0.4014 over three years for the acquisition of assets of Applied Optical Sciences. Additionally, stock-based compensation for the year ended December 31, 2021, was comprised of 140,000 shares under a restricted stock agreement the Company entered into in May of 2021. The restricted stock awards were valued at $84,000 of which $46,987 was recognized in 2021. The shares vest annually over two years with the first installment one year from the agreement; provide, however, if either party terminates the agreement at any time prior to the last date of it ending, then the shares will best, pro rata, for each month served since the most recent prior annual vesting date. The company recognized no related income tax benefit because our deferred tax assets are fully offset by a valuation allowance. The company issued 140,000 shares through restricted stock grants year ended December 31, 2021, and 2020. The company renewed a consulting agreement, extending services for an additional term of two sequential one-year periods. As compensation for the renewal, Mr. Donaghey is to receive for each year of service during the renewal term 70,000 shares of AERG common stock and options to purchase 200,000 shares of common stock at an exercise price of $0.61 per share, reflecting the fair market value of the common stock on the date of grant. 50% of the options vest on the first anniversary of the renewal, and the other 50% vest on the second anniversary, 50% of the common stock vests immediately and the remaining 50% on the first anniversary of the agreement. During the year ended December 31, 2021, the company issued 760,000 options to purchase common stock at an exercise price of $0.61 a share. The options vest over a period of three years from the date of the amendment. During the year ended December 31, 2021, the company issued 1,000,000 options to purchase common stock at an exercise price of $0.19 a share. The options vest over a period of three years from the date of the amendment. During the year ended December 31, 2021, the company issued 155,000 options to purchase common stock at an exercise price of $1.21 a share. The options vest over a period of three years from the date of the amendment. The following table summarizes the activity of our stock options for the years ended December 31, 2020 and 2021: Shares Weighted Average Weighted Average Contractual Term Outstanding Intrinsic Value Outstanding at January 1, 2020 32,900,000 0.1428 6.6 $ 4,731,000 Granted - - Exercised (900,000 ) 0.0700 Forfeited or expired - - Outstanding at December 31, 2020 32,000,000 $ 0.1419 5.6 $ 6,054,000 Granted 1,915,000 $ 0.7806 Exercised (4,500,000 ) $ 0.0856 Forfeited or expired (1,000,000 ) $ 0.3700 Outstanding at December 31, 2021 28,415,000 $ 0.1859 5.84 $ 60,640,900 Outstanding and exercisable at December 31, 2021 23,128,888 $ 0.1291 5.84 $ 50,673,665 We determine the fair value of option grant share-based awards at their grant date, using a Black-Scholes- Merton Option-Pricing Model applying the assumptions in the following table: For the year ended 2021 2020 Expected life (years) 2-3 N/A Dividend yield 0 % N/A Expected volatility 128-130 % N/A Risk free interest rates .05-.07 N/A As of December 31, 2021, there was approximately $764,000 of unrecognized compensation cost related to unvested stock options granted and outstanding, net of estimated forfeitures. The cost is expected to be recognized on a weighted average basis over a period of approximately one year. As of December 31, 2021, and December 31, 2020, the company recorded $223,000 and $892,000, respectively, in unrecognized stock-based compensation related to a lockup agreement on 5,000,000 shares of common stock in the acquisition of assets of AOS valued at $0.4014 per share, representing the closing price on the date of the contract which is amortized over 36 months. $669,000 and $669,000 was amortized for the year ended December 31, 2021, and 2020, respectively. Additionally, stock-based compensation for the year ended December 31, 2021, was comprised of 140,000 shares under a restricted stock agreement the Company entered into in May of 2021. The restricted stock awards were valued at $84,000 of which $46,987 was recognized in 2021. The shares vest annually over two years with the first installment one year from the agreement; provide, however, if either party terminates the agreement at any time prior to the last date of it ending, then the shares will best, pro rata, for each month served since the most recent prior annual vesting date The fair value of restricted stock and restricted stock units was estimated using the closing price of our common stock on the date of award and fully recognized upon vesting. Restricted stock activity for the year ended December 31, 2021 was as follows: Restricted Stock Outstanding Shares Weighted Outstanding at December 31, 2019 - Granted – restricted stock units and awards 75.000 0.35 Granted – performance based stock units - - Canceled - - Vested and converted to shares - - Outstanding at December 31, 2020 75,000 0.35 Granted – restricted stock units and awards 140,000 0.61 Granted – performance based stock units - Canceled - Vested and converted to shares - Outstanding at December 31, 2021 215,000 0.52 We determine the fair value of warrant grant share-based awards at their grant date, using a Black-Scholes- Merton Option-Pricing Model applying the assumptions in the following table: For the year ended 2021 2020 Expected life (years) N/A 1.0 Dividend yield N/A 0 % Expected volatility N/A 125.19 % Risk free interest rates N/A 0.14 % Weighted average fair value of warrants at grant date $ N/A .308 Warrant Activity Shares Weighted Weighted Outstanding at January 1, 2020 3,675,000 $ 0.0632 6.96 Granted 50,000 0.0500 Exercised (175,000 ) 0.0700 Forfeited or expired - - Outstanding at December 31, 2020 3,550,000 $ 0.0627 6.17 Granted - - - Exercised (1,650,000 ) 0.0652 Forfeited or expired (125,000 ) 0.0599 Outstanding at December 31, 2021 1,775,000 $ 0.0599 7.43 Outstanding and exercisable at December 31, 2021 1,775,000 0.0599 7.43 Warrants Outstanding Warrants Exercisable Weighted Avg. Remaining Shares Contractual Weighted Avg. Shares Weighted Avg. Range of Exercise Prices Outstanding Life in Years Exercise Price Exercisable Exercise Price $0.05 - $0.07 1,775,000 7.43 $ 0.0599 1,775,000 $ 0.0599 1,775,000 7.43 $ 0.0599 1,775,000 $ 0.0599

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 7 – COMMITMENTS AND CONTINGENCIES Operating Leases In May 2016, we moved and entered into a month-to-month lease agreement to lease office space in Tucson, Arizona. In May 2019, we acquired Applied Optical Sciences and assumed the month-to-month lease for office and laboratory space also in Tucson, Arizona. Rent expense was approximately $155,000 and $49,000 for 2021 and 2020, respectively. In March 2021, we signed a five-year lease for a 13,000 square foot laboratory/office space here in Tucson. The lease term begins May 1, 2021, and ends on April 30, 2026. The base rent is $6.7626 per rentable square foot for year one, and escalates to $9.2009 in year two, $11.4806 in year three, $13.1740 in year four and $14.9306 in year five, plus certain operating expenses and taxes. At December 31, 2021, we had approximately $112,000 in future minimum lease payments due in less than a year. The below table presents the future minimum lease payments due reconciled to lease liabilities. Operating Lease For the fiscal years ending December 31, 2021: 2022 $ 112,141 2023 143,325 2024 168,577 2025 191,779 Thereafter 66,536 Total undiscounted lease payments 682,358 Present value discount, less interest 98,942 Lease Liability $ 583,416 Guarantees We agree to indemnify our officers and directors for certain events or occurrences arising as a result of the officers or directors serving in such capacity. The maximum amount of future payments that we could be required to make under these indemnification agreements is unlimited. However, we maintain a director’s and officer’s liability insurance policy that limits our exposure and enables us to recover a portion of any future amounts paid. As a result, we believe the estimated fair value of these indemnification agreements is minimal because of our insurance coverage and we have not recognized any liabilities for these agreements as of December 31, 2021, and 2020. Litigation As previously reported, on July 3, 2018, we commenced a lawsuit in the Court of Chancery of the State of Delaware against the company’s former director and principal executive officer George Farley (“Farley”) and AnneMarieCo LLC (“AMC”). The parties settled the lawsuit via a written settlement agreement dated September 24, 2020. Under the agreement, 20,000,000 of the 25,000,000 shares originally issued to Farley (20,000,000 of which were transferred to AMC) were invalidated, the remaining 5,000,000 shares being deemed valid under Section 205 of the Delaware General Corporation Law. The agreement calls for the company to repurchase the remaining 5,000,000 shares at a price of $0.30 per share for an aggregate purchase price of $1,500,000. The agreement also provided for the release and return to the company of funds in the amount of $582,377.26, plus interest, securing the bond posted by the company in connection with the preliminary injunction issued in the litigation. The agreement also contains standard mutual general release and confidentiality provisions. Approximately, $206,000 accrued compensation was forgone as per settlement agreement was shown as gain on settlement. In a related matter, on February 8, 2019, the company filed a complaint against Stein Riso Mantel McDonough, LLP (“Stein Riso”), its former counsel, in the United States District Court for the Southern District of New York. The parties settled the lawsuit via a written settlement agreement dated October 2, 2020. Pursuant to the agreement, Stein Riso paid the company three million dollars ($3,000,000) and returned to the company ten million (10,000,000) shares of the company’s common stock, par value $0.001 per share. Stein Riso entered into the Settlement Agreement without any admission of liability. The parties filed a Stipulation of Dismissal with Prejudice as to all claims asserted or which could have been asserted in the lawsuit. The agreement also contains standard mutual general release and confidentiality provisions. On July 3, 2019, Gusrae, Kaplan & Nusbaum and its partner, Ryan Whalen filed a complaint in the United States District Court for the Southern District of New York against the company, its directors, officers, attorneys and a consultant. The action alleged libel, securities fraud and related claims. The company filed a motion to dismiss the complaint on October 24, 2019. On December 13, 2019, Gusrae Kaplan and Mr. Whalen filed an opposition to the company’s motion. On January 10, 2020, the company filed a reply brief. The United States District Court has not ruled on the motion. On August 5, 2021, the plaintiffs filed a Notice of Voluntary Dismissal of the action without prejudice. On June 15, 2020, Grace A.C. Dearmin, as the Administrator of the Estate of Thomas Carr Dearmin, filed a cross-complaint against the company and company directors Jonathan Barcklow and Bradford Adamczyk, alleging causes of action against them for Breach of Contract and Conversion. The causes of action against the company allege that the company’s board of directors voted to compensate its former CEO and director, Thomas Dearmin, as reflected in board meeting minutes dated May 11, 2018, and June 25, 2018, but failed to pay compensation owed to Mr. Dearmin. These causes of action further allege that, if incentive milestones of the company’s stock price were reached, Mr. Dearmin’s estate is owed up to 5 million shares of company common stock, or the current monetary value of that stock. On November 17, 2020, the company, Mr. Barcklow and Mr. Adamczyk filed motions to dismiss the cross-complaint against them on substantive and jurisdictional grounds. On February 8, 2021, the court granted the motion to dismiss on personal jurisdiction grounds as to the company, Mr. Barcklow and Mr. Adamczyk. On January 15, 2021, the company filed a complaint in the United States District Court, Southern District of New York, against Gusrae, Kaplan & Nusbaum and Ryan Whalen for malpractice and breach of New York Rules of Professional Conduct by both parties as former counsel to the company. On May 28, 2021, Gusrae, Kaplan & Nusbaum and Mr. Whalen filed a motion to dismiss the complaint. On June 25, 2021, the company filed an opposition to the motion. On July 13, 2021, Gusrae Kaplan & Nusbaum and Mr. Whalen filed their reply brief. The United States District Court has not yet ruled on the motion. On September 7, 2021, Gusrae Kaplan & Nusbaum and its partner Ryan Whalen filed a complaint in the New York Supreme Court against the company, its directors, officers, attorneys and a consultant, alleging a single claim for defamation per se based on the same conduct underlying their claim of libel in their voluntarily dismissed federal court action. The company filed a motion to dismiss the complaint on October 29, 2021, which motion included a request for sanctions for filing a frivolous complaint. Gusrae Kaplan & Nusbaum and Mr. Whalen filed their opposition to the company’s motion to dismiss on January 13, 2022. The company filed its reply brief on February 17, 2022. On March 9, 2022, the company received notice that the court had scheduled oral arguments on the motion to dismiss for May 23, 2022. As with any litigation, the company cannot predict the outcome with certainty, but the company expects to provide further updates on the status of the litigation as circumstances warrant. We may, from time to time, be involved in legal proceedings arising from the normal course of business.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 8 – INCOME TAXES An analysis of the difference between the expected federal income tax for the years ended December 31, 2021, and 2020, and the effective income tax rate is as follows: 2021 2020 Noncurrent deferred tax assets (liabilities): Deferred Tax Assets $ $ Accrued Compensation 1,895,848 1,380,954.94 Fixed assets and intangibles (114,167 ) (70,473.82 ) Net Operating Loss Carryforwards and Credits 15,070,176 14,378,365 Total Deferred Tax Assets $ 16,851,857 $ 15,688,846 Valuation allowance (16,851,857 ) (15,688,846 ) Net deferred tax / (liabilities) $ - $ - Tax effects of temporary differences at December 31, 2021 and December 31, 2020 are as follows: 2021 2020 Taxes calculated at federal rate $ (1,139,345 ) 21.0 % $ (634,101 ) 21.0 % State income tax, net of federal benefit (195,688 ) 3.6 % (90,903 ) 3.8 % Change in Valuation Allowance 1,163,011 -21.4 % 463,091 -21.7 % Expiration of tax attributes 139,331 -2.6 % 161,254 -3.1 % Prior period adjustment 48,152 -0.9 % (49,105 ) 0.0 % Permanent Items (15,460 ) 0.3 % 149,763 0.0 % Provision (benefit) for taxes $ (0 ) 0.0 % $ (0 ) 0.0 % Deferred tax assets and liabilities are computed by applying the federal and state income tax rates in effect to the gross amounts of temporary differences and other tax attributes, such as net operating loss carry-forwards. In assessing if the deferred tax assets will be realized, the company considers whether it is more likely than not that some or all of these deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which these deductible temporary differences reverse. During the year ended December 31, 2021, the deferred tax assets and the valuation allowance increased by $1,163,011 mainly as a result of current year tax loss. As of December 31, 2021, we have cumulative federal and Arizona net operating loss carryforwards of approximately $67.2 million and $9.6 million, respectively, which can be used to offset future income subject to taxes. Of the $67.2 million, of Federal net operating loss carryforwards, $57.8 begin to expire in 2021. The remaining balance of $9.4 million is limited in annual usage of 80% of current years taxable income but do not have an expiration. Arizona net operating loss carryforwards began to expire in 2021. In addition, there are federal net operating loss carryforwards of approximately $27.0 million from USHG related to pre-merger losses. We also have pre-merger federal capital loss carryforwards of approximately $520,000. As of December 31, 2021, we had cumulative unused research and development tax credits of approximately $239,000 and $340,000, which can be used to reduce future federal and Arizona income taxes, respectively. As of December 31, 2021, we have cumulative unused federal minimum tax credit carryforwards from USHG of approximately $244,000. The federal minimum tax credit carryforwards are not subject to expiration under current federal tax law. Utilization of our USHG pre-merger net operating loss carryforwards and tax credits is subject to substantial annual limitations due to the ownership change limitations provided by the Internal Revenue Code and similar state provisions. Such an annual limitation could result in the expiration of the net operating loss carryforwards and tax credit carryforwards before utilization. We have unrecognized tax benefits attributable to losses and minimum tax credit carryforwards that were incurred by USHG prior to the merger in March 2004 as follows: Balance at December 31, 2019 $ 9,635,824 Additions related to prior year tax positions - Additions related to current year tax positions - Reductions related to prior year tax positions and settlements Balance at December 31, 2020 $ 9,635,824 Additions related to prior year tax positions - Additions related to current year tax positions - Reductions related to prior year tax positions and settlements - Balance at December 31, 2021 $ 9,635,824 These benefits are not recognized as a result of uncertainty regarding the utilization of the loss carryforwards and minimum tax credits. If in the future we utilize the attributes and resolve the uncertainty in our favor, the full amount will favorably impact our effective income tax rate. The company considers the U.S. and Arizona to be major tax jurisdictions. As of December 31, 2020, for federal tax purposes the tax years 2019-2021 and for Arizona the tax years 2016 through 2021 remain open to examination. The company currently does not expect any material changes to unrecognized tax positions within the next twelve months. We recognize interest and penalties related to unrecognized tax benefits in income tax expense. As of December 31, 2021, and 2020, we had no accrued interest or penalties related to our unrecognized tax benefits.

Subsequent Event

Subsequent Event	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENT	NOTE 9 – SUBSEQUENT EVENT The company’s management has evaluated subsequent events occurring after December 31, 2021, the date of our most recent balance sheet, through the date our financial statements were issued. In January 2022, we issued two options totaling 1,390,000 shares, each with a life of 10 years and an exercise price of $2.40. Subsequent to year end, the Company issued 130,416 shares of common stock in relation to a 2019 compensation agreement. Subsequent to the year ended December 31, 2021, the company entered into a $175,434.65 financing agreement to finance its Directors and Officers insurance premiums.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements include the accounts of Applied Energetics, Inc. and its wholly owned subsidiary North Star Power Engineering, Inc. (“North Star”) (collectively, “company,” “Applied Energetics,” “AERG”, “we,” “our” or “us”). All intercompany balances and transactions have been eliminated.
Going Concern	Going Concern The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. For the year ended December 31, 2021, the company incurred a net loss of approximately $5,425,000, had negative cash flows from operations of approximately $3,214,000 and may incur additional future losses due to the reduction in Government contract activity. At December 31, 2021, the company had total current assets of approximately $3,706,000 and total current liabilities of approximately $1,416,000 resulting in working capital of approximately $2,290,000. At December 31, 2021, the company had cash of approximately $3,663,000. As of December 31, 2021, the company had cash of approximately $3,663,000. Based on the company’s current business plan, it believes its cash balance as of the date of this filing will be sufficient to meet its anticipated cash requirements for the next twelve months. However, there can be no assurance that the current business plan will be achievable. Such conditions raise substantial doubts about the company’s ability to continue as a going concern for one year from the date the financial statements are issued. The company’s existence is dependent upon management’s ability to develop profitable operations. Management is devoting substantially all of its efforts to developing its business and raising capital and there can be no assurance that the company’s efforts will be successful. No assurance can be given that management’s actions will result in profitable operations or the resolution of its liquidity problems. The accompanying consolidated financial statements do not include any adjustments that might result should the company be unable to continue as a going concern. The ongoing COVID-19 pandemic contributes to this uncertainty. In order to improve the company’s liquidity, the company’s management is actively pursuing additional equity financing through discussions with investment bankers and private investors. There can be no assurance that the company will be successful in its effort to secure additional equity financing. The financial statements do not include any adjustments relating to the recoverability of assets and the amount or classification of liabilities that might be necessary should the company be unable to continue as a going concern. Applied Energetics, Inc. is a corporation organized and existing under the laws of the State of Delaware. Our executive office and laboratory space are located at 9070 S. Rita Road, Suite 1500, Tucson, Arizona, 85747, and our telephone number is (520) 628-7415.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and accompanying notes. Management bases its assumptions on historical experiences and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. In addition, management considers the basis and methodology used in developing and selecting these estimates, the trends in and amounts of these estimates, specific matters affecting the amount of and changes in these estimates, and any other relevant matters related to these estimates, including significant issues concerning accounting principles and financial statement presentation. Such estimates and assumptions could change in the future as more information becomes known which could impact the amounts reported and disclosed herein. Significant estimates include revenue recognition, carrying amounts of long-lived assets, valuation assumptions for share-based payments, evaluation of debt modification accounting, effective borrowing rate determinations, analysis of fair value transferred upon debt extinguishment, valuation and calculation of measurements of income tax assets and liabilities and valuation of debt discount related to beneficial conversion features.
Net Loss Attributable to Common Stockholders	Net Loss Attributable to Common Stockholders Basic loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period before giving effect to stock options, stock warrants, restricted stock units and convertible securities outstanding, which are considered to be dilutive common stock equivalents. Diluted net loss per common share is calculated based on the weighted average number of common and potentially dilutive shares outstanding during the period after giving effect to dilutive common stock equivalents. Contingently issuable shares are included in the computation of basic loss per share when issuance of the shares is no longer contingent. The number of warrants, options, restricted stock units and our Series A Convertible Preferred Stock, which were not included in the computation of earnings per share because the effect was antidilutive, was 30,343,602 and 35,612,091 for the years ended December 31, 2021 and 2020, respectively.
Fair Value of Current Assets and Liabilities	Fair Value of Current Assets and Liabilities The carrying amount of accounts payable approximate fair value due to the short maturity of these instruments.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash equivalents are investments in money market funds or securities with an initial maturity of three months or less. We maintain our cash balances at a commercial bank, and, at times, balances exceed FDIC limits. As of December 31, 2021, $3,412,615 of our cash balance was uninsured.
Income Taxes	Income Taxes Deferred tax assets and liabilities are recognized currently for the future tax consequences attributable to the temporary differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets if it is more likely than not that such assets will not be realized. Our valuation allowance is currently 100% of our assets. We consider all available evidence, both positive and negative, to determine whether, based on the weight of that evidence, a valuation allowance is needed for some portion or all of a net deferred tax asset. Judgment is used in considering the relative impact of negative and positive evidence. In arriving at these judgments, the weight given to the potential effect of negative and positive evidence is commensurate with the extent to which it can be objectively verified. We record a valuation allowance to reduce our deferred tax assets and review the amount of such allowance annually. When we determine certain deferred tax assets are more likely than not to be utilized, we will reduce our valuation allowance accordingly.
Revenue Recognition	Revenue Recognition The company recognizes revenue in accordance with ASC Topic 606 – Revenue from Contracts with Customers (“ASC 606”) to depict the transfer of control to the company’s customers in an amount reflecting the consideration the company expects to be entitled. The company determines revenue recognition through the following steps: i. Identification of the contract, or contracts, with a customer ii. Identification of the performance obligations in the contract iii. Determination of the transaction price iv. Allocation of the transaction price to the performance obligations in the contract v. Recognition of revenue, when, or as, the company satisfied the performance obligation The company generated revenue from its customer by preparing a technical report. The company’s single performance obligation was to deliver the final technical report detailing the findings of the company’s investigations. The fee for the report was fixed.
Share-Based Payments	Share-Based Payments Employee stock-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period. The fair value of each option grant is estimated at the date of grant using the Black-Scholes-Merton option valuation model. We make the following assumptions relative to this model: (i) the annual dividend yield is zero as we do not pay dividends on common stock, (ii) the weighted-average expected life is based on a midpoint scenario, where the expected life is determined to be half of the time from grant to expiration, regardless of vesting, (iii) the risk free interest rate is based on the U.S. Treasury security rate for the expected life, and (iv) the volatility is based on the level of fluctuations in our historical share price for a period equal to the weighted-average expected life. We estimate forfeitures when recognizing compensation expense and adjust this estimate over the requisite service period should actual forfeitures differ from such estimates. Changes in estimated forfeitures are recognized through a cumulative adjustment, which is recognized in the period of change, and which impacts the amount of unamortized compensation expense to be recognized in future periods.
Significant Concentrations and Risks	Significant Concentrations and Risks We maintain cash balances at a commercial bank, and, at times, balances exceed FDIC limits. As of December 31, 2021, $3,412,615 of our cash balance was uninsured.

Notes Payable (Tables)

Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Schedule of reconciles notes payable	December 31, December 31, Beginning balance $ 2,681,157 $ 4,967,890 Notes payable 117,209 4,456,760 Accrued interest 1,385 297,849 Transfer from prepaid - 108,064 Initial beneficial conversion feature - (919,000 ) Amortize beneficial conversion feature - 919,000 Payments on notes payable (1,646,513 ) (1,480,951 ) Repayment of interest - (152,603 ) Extinguishment of Debt (81,550 ) - Converted into common stock (47,498 ) (5,515,852 ) Total 1,024,190 2,681,157 Less-Notes payable - current 1,024,190 (1,547,695 ) Notes payable - non-current $ - $ 1,133,462
Schedule of future principal payments	2022 $ 1,024,190 Thereafter - Total $ 1,024,190

Stockholders_ Deficit (Tables)

Stockholders’ Deficit (Tables)	12 Months Ended
	Dec. 31, 2021
Stockholders' Equity Note [Abstract]
Schedule of stock options	Shares Weighted Average Weighted Average Contractual Term Outstanding Intrinsic Value Outstanding at January 1, 2020 32,900,000 0.1428 6.6 $ 4,731,000 Granted - - Exercised (900,000 ) 0.0700 Forfeited or expired - - Outstanding at December 31, 2020 32,000,000 $ 0.1419 5.6 $ 6,054,000 Granted 1,915,000 $ 0.7806 Exercised (4,500,000 ) $ 0.0856 Forfeited or expired (1,000,000 ) $ 0.3700 Outstanding at December 31, 2021 28,415,000 $ 0.1859 5.84 $ 60,640,900 Outstanding and exercisable at December 31, 2021 23,128,888 $ 0.1291 5.84 $ 50,673,665
Schedule of black-scholes- merton option-pricing model applying the assumptions	For the year ended 2021 2020 Expected life (years) 2-3 N/A Dividend yield 0 % N/A Expected volatility 128-130 % N/A Risk free interest rates .05-.07 N/A For the year ended 2021 2020 Expected life (years) N/A 1.0 Dividend yield N/A 0 % Expected volatility N/A 125.19 % Risk free interest rates N/A 0.14 % Weighted average fair value of warrants at grant date $ N/A .308
Schedule of fair value of restricted stock and restricted stock units	Restricted Stock Outstanding Shares Weighted Outstanding at December 31, 2019 - Granted – restricted stock units and awards 75.000 0.35 Granted – performance based stock units - - Canceled - - Vested and converted to shares - - Outstanding at December 31, 2020 75,000 0.35 Granted – restricted stock units and awards 140,000 0.61 Granted – performance based stock units - Canceled - Vested and converted to shares - Outstanding at December 31, 2021 215,000 0.52
Schedule of unrecognized stock-based compensation related to unvested restricted stock, net of estimated forfeitures	Warrant Activity Shares Weighted Weighted Outstanding at January 1, 2020 3,675,000 $ 0.0632 6.96 Granted 50,000 0.0500 Exercised (175,000 ) 0.0700 Forfeited or expired - - Outstanding at December 31, 2020 3,550,000 $ 0.0627 6.17 Granted - - - Exercised (1,650,000 ) 0.0652 Forfeited or expired (125,000 ) 0.0599 Outstanding at December 31, 2021 1,775,000 $ 0.0599 7.43 Outstanding and exercisable at December 31, 2021 1,775,000 0.0599 7.43
Schedule of range exercise prices warrants outstanding and exercisable	Warrants Outstanding Warrants Exercisable Weighted Avg. Remaining Shares Contractual Weighted Avg. Shares Weighted Avg. Range of Exercise Prices Outstanding Life in Years Exercise Price Exercisable Exercise Price $0.05 - $0.07 1,775,000 7.43 $ 0.0599 1,775,000 $ 0.0599 1,775,000 7.43 $ 0.0599 1,775,000 $ 0.0599

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Schedule of future minimum lease payments	Operating Lease For the fiscal years ending December 31, 2021: 2022 $ 112,141 2023 143,325 2024 168,577 2025 191,779 Thereafter 66,536 Total undiscounted lease payments 682,358 Present value discount, less interest 98,942 Lease Liability $ 583,416

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedue of deferred tax assets	2021 2020 Noncurrent deferred tax assets (liabilities): Deferred Tax Assets $ $ Accrued Compensation 1,895,848 1,380,954.94 Fixed assets and intangibles (114,167 ) (70,473.82 ) Net Operating Loss Carryforwards and Credits 15,070,176 14,378,365 Total Deferred Tax Assets $ 16,851,857 $ 15,688,846 Valuation allowance (16,851,857 ) (15,688,846 ) Net deferred tax / (liabilities) $ - $ -
Schedule of federal income tax and effective income tax	2021 2020 Taxes calculated at federal rate $ (1,139,345 ) 21.0 % $ (634,101 ) 21.0 % State income tax, net of federal benefit (195,688 ) 3.6 % (90,903 ) 3.8 % Change in Valuation Allowance 1,163,011 -21.4 % 463,091 -21.7 % Expiration of tax attributes 139,331 -2.6 % 161,254 -3.1 % Prior period adjustment 48,152 -0.9 % (49,105 ) 0.0 % Permanent Items (15,460 ) 0.3 % 149,763 0.0 % Provision (benefit) for taxes $ (0 ) 0.0 % $ (0 ) 0.0 %
Schedule of unrecognized tax benefits attributable to losses and minimum tax credit carryforwards	Balance at December 31, 2019 $ 9,635,824 Additions related to prior year tax positions - Additions related to current year tax positions - Reductions related to prior year tax positions and settlements Balance at December 31, 2020 $ 9,635,824 Additions related to prior year tax positions - Additions related to current year tax positions - Reductions related to prior year tax positions and settlements - Balance at December 31, 2021 $ 9,635,824

Organization of Business, Goi_2

Organization of Business, Going Concern and Summary of Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Organization of Business, Going Concern and Summary of Significant Accounting Policies (Details) [Line Items]
Net loss	$ 5,425,000
Negative cash flows from operations	3,214,000
Total current assets	$ 3,706,000
Issuance of preferred stock (in Shares)	30,343,602	35,612,091
Cash balance	$ 3,412,615
Valuation allowance	100.00%
Cash uninsured	$ 3,412,615
Government contract [Member]
Organization of Business, Going Concern and Summary of Significant Accounting Policies (Details) [Line Items]
Current liability	1,416,000
Working capital	2,290,000
Total cash	$ 3,663,000

New Accounting Standards (Detai

New Accounting Standards (Details)	12 Months Ended
	Dec. 31, 2021USD ($)
Accounting Standards Update and Change in Accounting Principle [Abstract]
Recognition of right of use asset	$ 617,569
Recognition of lease liability	617,569
Right of use asset	544,670
Lease liability	$ 583,415

Notes Payable (Details)

Notes Payable (Details) - USD ($)

Apr. 12, 2021

Mar. 12, 2021

Jun. 30, 2021

Mar. 25, 2021

Apr. 28, 2020

May 24, 2019

Dec. 31, 2021

Dec. 31, 2020

Nov. 24, 2022

May 24, 2022

Nov. 19, 2021

May 24, 2021

Feb. 10, 2021

Notes Payable (Details) [Line Items]

Issued of stock value

$ 75,250

Payments

$ 1,000,000

1,547,695

$ 500,000

$ 500,000

$ 500,000

Remaining due

$ 500,000

Debt discount

2,500,000

Promissory note

1,500,000

Payment, description

the company entered into a loan agreement with Alliance Bank of Arizona, N.A. for a loan in the amount of $132,760 pursuant to the Paycheck Protection Program (the “PPP”) under the Coronavirus Aid, Relief, and Economic Security Act enacted on March 27, 2020 (the “CARES Act”). This loan is evidenced by a promissory note dated April 27, 2020, and matures two years from the disbursement date. This loan bears interest at a rate of 1.00% per annum, with the first nine months of interest deferred. Principal and interest are payable monthly commencing nine months after the disbursement date and may be prepaid by the company at any time prior to maturity with no prepayment penalties.

Proceeds amount

$ 81,550

4,324,000

PPP principal amount

22,804

PPP interest amount

1,385

Additional payment total

$ 29,306

Accrue interest

1.00%

Financial amount

$ 156,279

Maturity date

Mar. 12, 2022

Interest fixed rate

6.50%

Current asset

$ 39,070

$ 43,391

39,352

Principal amount

$ 13,024

Interest payments

$ 117,209

Outstanding balance

0

Convertible notes payable

$ 47,498

Note payable description

The company’s note payable balance of $1,204,190 is due within the next twelve months, in accordance with the terms of note payable. Of the remaining $1,204,190, $1,000,000 consists of two remaining payments of $500,000, due on May 24, 2022 and November 24, 2022, which is the remaining balance on the note payable that the company assumed as part of the agreement to acquire Applied Optical Sciences. In accordance with the terms of note payable, the company made the first three payments of $500,000 on February 10, 2021, May 24, 2021, and November 19, 2021.

Directors and Officers insurance premiums

$ 175,434.65

PPP Forgiveness [Member]

Notes Payable (Details) [Line Items]

PPP principal amount

80,594

PPP interest amount

$ 956

AOS [Member]

Notes Payable (Details) [Line Items]

Issued of stock value

$ 2,500,000

Common Stock [Member]

Notes Payable (Details) [Line Items]

Issued of stock value

$ 1,075

Notes payable (in Shares)

158,329

Forecast [Member]

Notes Payable (Details) [Line Items]

Remaining due

$ 500,000

Notes Payable (Details) - Sched

Notes Payable (Details) - Schedule of reconciles notes payable - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of reconciles notes payable [Abstract]
Beginning balance	$ 2,681,157	$ 4,967,890
Notes payable	117,209	4,456,760
Accrued interest	1,385	297,849
Transfer from prepaid		108,064
Initial beneficial conversion feature		(919,000)
Amortize beneficial conversion feature		919,000
Payments on notes payable	(1,646,513)	(1,480,951)
Repayment of interest		(152,603)
Extinguishment of Debt	(81,550)
Converted into common stock	(47,498)	(5,515,852)
Total	1,024,190	2,681,157
Less-Notes payable - current	1,024,190	(1,547,695)
Notes payable - non-current		$ 1,133,462

Notes Payable (Details) - Sch_2

Notes Payable (Details) - Schedule of future principal payments	Dec. 31, 2021USD ($)
Schedule of future principal payments [Abstract]
2022	$ 1,024,190
Thereafter
Total	$ 1,024,190

Deferred Compensation (Details)

Deferred Compensation (Details) - USD ($)	1 Months Ended	12 Months Ended
	May 24, 2019	Dec. 31, 2021	Dec. 31, 2020
Deferred Compensation [Abstract]
Promissory note issued	$ 2,500,000
Deferred compensation	$ 2,500,000
Amortization of deferred compensation		$ 833,333	$ 833,333
Remaining deferred compensation		$ 416,667	$ 1,250,000

Due to Related Parties (Details

Due to Related Parties (Details)	1 Months Ended
	Jul. 31, 2018USD ($)
CEO [Member]
Due to Related Parties (Details) [Line Items]
Deposited	$ 50,000

Stockholders_ Deficit (Details)

Stockholders’ Deficit (Details)	1 Months Ended			12 Months Ended
	Apr. 30, 2020USD ($)shares	Feb. 29, 2020USD ($)shares	Jan. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)shares
Stockholders’ Deficit (Details) [Line Items]
Common stock, shares authorized				500,000,000	500,000,000
Preferred stock, shares authorized				2,000,000
Common stock shares			2,010,000
Exercise price per share (in Dollars per Share) | $ / shares			0.07
Option exercise (in Dollars) | $				$ 108,000
Stock-based compensation amount (in Dollars) | $				$ 1,236,806
Series A convertible preferred stock, issued				13,602	13,602
Accured dividends (in Dollars) | $				$ 295,000
Series A convertible preferred stock, liquidation preference (in Dollars per share) | $ / shares				$ 25
Series A convertible preferred stock, dividend rate				6.50%
Weighted average of the last sales prices				95.00%
Dividend rate increase				10.00%
Preferred stock conversion price per share (in Dollars per share) | $ / shares				$ 12
Stockholders equity, description				If the closing sale price of the common stock is greater than 140% of the conversion price on 20 out of 30 trading days, the company may redeem the Series A Preferred Stock in whole or in part at any time through October 31, 2010, upon at least 30 days’ notice, at a redemption price, payable in cash, equal to 100% of the liquidation preference of the shares to be redeemed, plus unpaid dividends thereon to, but excluding, the redemption date, subject to certain conditions. In addition, beginning November 1, 2010, the company may redeem the Series A Preferred Stock in whole or in part, upon at least 30 days’ notice, at a redemption price, payable in cash, equal to 100% of the liquidation preference of the Series A Preferred Stock to be redeemed, plus unpaid dividends thereon to, but excluding, the redemption date, under certain conditions.
Common stock discount shares description				The purchase price is payable, at the corporation’s option, (x) in cash, (y) in shares of the common stock at a discount of 5% from the fair market value of Common Stock on the Purchase Date (i.e. valued at a 95% discount of the Common Stock on the Purchase Date), or (z) any combination thereof.
Reserved a total possible issuance under the plan				50,000,000
Total stock-based compensation expense for grants (in Dollars) | $				$ 1,232,256	$ 1,501,000
Stock based compensation description				The $1,236,806 stock-based compensation for the year ended December 31, 2021, was comprised of $520,819 option expense and $669,000 was the amortization of 5,000,000 shares of stock valued at $0.4014 over three years for the acquisition of assets of Applied Optical Sciences.
Share based compensation of restricted stock agreement shares				140,000
Restricted stock awards value (in Dollars) | $				$ 84,000
Recognized restricted stock awards value (in Dollars) | $				$ 46,987
Restricted stock, grants description				The company issued 140,000 shares through restricted stock grants year ended December 31, 2021, and 2020. The company renewed a consulting agreement, extending services for an additional term of two sequential one-year periods. As compensation for the renewal, Mr. Donaghey is to receive for each year of service during the renewal term 70,000 shares of AERG common stock and options to purchase 200,000 shares of common stock at an exercise price of $0.61 per share, reflecting the fair market value of the common stock on the date of grant. 50% of the options vest on the first anniversary of the renewal, and the other 50% vest on the second anniversary, 50% of the common stock vests immediately and the remaining 50% on the first anniversary of the agreement.
Unrecognized stock based compensation (in Dollars) | $				$ 764,000
Weighted average basis over a period				1 year
Restricted stock agreement shares description				Additionally, stock-based compensation for the year ended December 31, 2021, was comprised of 140,000 shares under a restricted stock agreement the Company entered into in May of 2021. The restricted stock awards were valued at $84,000 of which $46,987 was recognized in 2021.
Business Combination [Member]
Stockholders’ Deficit (Details) [Line Items]
Issuable in acquisition, description				As of December 31, 2021, and December 31, 2020, the company recorded $223,000 and $892,000, respectively, in unrecognized stock-based compensation related to a lockup agreement on 5,000,000 shares of common stock in the acquisition of assets of AOS valued at $0.4014 per share, representing the closing price on the date of the contract which is amortized over 36 months. $669,000 and $669,000 was amortized for the year ended December 31, 2021, and 2020, respectively.
Subscription Agreements [Member]
Stockholders’ Deficit (Details) [Line Items]
Shares Issued	1,770,333
Subscription Agreements (in Dollars) | $	$ 531,000
Private Placement [Member]
Stockholders’ Deficit (Details) [Line Items]
Common stock shares				4,054,665
Price per share (in Dollars per share) | $ / shares				$ 0.75
Cash proceeds (in Dollars) | $				$ 3,041,000
Private Placement1 [Member]
Stockholders’ Deficit (Details) [Line Items]
Common stock shares				7,056,250
Price per share (in Dollars per share) | $ / shares				$ 0.32
Cash proceeds (in Dollars) | $				$ 2,258,000
Series A Preferred Stock [Member]
Stockholders’ Deficit (Details) [Line Items]
Series A convertible preferred stock, issued				13,602	13,602
Liquidation preference				7.50%
Minimum [Member]
Stockholders’ Deficit (Details) [Line Items]
Liquidation preference				1.00%
Maximum [Member]
Stockholders’ Deficit (Details) [Line Items]
Liquidation preference				6.50%
Common Stock [Member]
Stockholders’ Deficit (Details) [Line Items]
Common stock, shares authorized				500,000,000
Common stock value (in Dollars) | $		$ 510,000	$ 603,000
Common stock shares		1,700,000		158,329
Issue of warrants			25,000
Option exercise (in Dollars) | $				$ 1,650
Shares issued for convertible notes				47,498
Warrant [Member]
Stockholders’ Deficit (Details) [Line Items]
Common stock shares				800,000
Warrant Exercise (in Dollars) | $	$ 11,000
Shares Issued	150,000
Option exercise (in Dollars) | $	$ 63,000
Option exercise	900,000
Stock value issued for exercise of warrants				800,000
Warrant exercise price per share (in Dollars per share) | $ / shares				$ 0.07
Restricted Stock [Member]
Stockholders’ Deficit (Details) [Line Items]
Common stock shares				31,250
Stock value issued for restricted stock agreement (in Dollars) | $				$ 4,550
Warrant One [Member]
Stockholders’ Deficit (Details) [Line Items]
Common stock shares				250,000
Stock value issued for exercise of warrants				250,000
Warrant exercise price per share (in Dollars per share) | $ / shares				$ 0.06
Warrant Two [Member]
Stockholders’ Deficit (Details) [Line Items]
Common stock shares				50,000
Stock value issued for exercise of warrants				50,000
Warrant exercise price per share (in Dollars per share) | $ / shares				$ 0.06
Warrant Three [Member]
Stockholders’ Deficit (Details) [Line Items]
Common stock shares				100,000
Stock value issued for exercise of warrants				100,000
Warrant exercise price per share (in Dollars per share) | $ / shares				$ 0.07
Warrant Four [Member]
Stockholders’ Deficit (Details) [Line Items]
Common stock shares				200,000
Stock value issued for exercise of warrants				200,000
Warrant exercise price per share (in Dollars per share) | $ / shares				$ 0.06
Warrant Five [Member]
Stockholders’ Deficit (Details) [Line Items]
Common stock shares				125,000
Stock value issued for exercise of warrants				125,000
Warrant exercise price per share (in Dollars per share) | $ / shares				$ 0.06
Warrant Six [Member]
Stockholders’ Deficit (Details) [Line Items]
Common stock shares				60,000
Stock value issued for exercise of warrants				60,000
Warrant exercise price per share (in Dollars per share) | $ / shares				$ 0.06
Warrant Seven [Member]
Stockholders’ Deficit (Details) [Line Items]
Common stock shares				65,000
Stock value issued for exercise of warrants				65,000
Warrant exercise price per share (in Dollars per share) | $ / shares				$ 0.06
Options [Member]
Stockholders’ Deficit (Details) [Line Items]
Common stock shares				1,005,682
Common stock option exercise				1,090,910
Stock option exercise price Per share (in Dollars per share) | $ / shares				$ 0.05
Options to purchase common stock				760,000
Common stock exercise price (in Dollars per share) | $ / shares				$ 0.61
Options vest over a period				3 years
Options One [Member]
Stockholders’ Deficit (Details) [Line Items]
Common stock shares				259,741
Common stock option exercise				500,000
Stock option exercise price Per share (in Dollars per share) | $ / shares				$ 0.37
Options to purchase common stock				1,000,000
Common stock exercise price (in Dollars per share) | $ / shares				$ 0.19
Options vest over a period				3 years
Options Two [Member]
Stockholders’ Deficit (Details) [Line Items]
Common stock shares				475,000
Common stock option exercise				500,000
common stock withheld with exercise				25,000
Options to purchase common stock				155,000
Common stock exercise price (in Dollars per share) | $ / shares				$ 1.21
Options vest over a period				3 years
Options Three [Member]
Stockholders’ Deficit (Details) [Line Items]
Common stock shares				482,143
Common stock option exercise				500,000
common stock withheld with exercise				17,857
Option Four [Member]
Stockholders’ Deficit (Details) [Line Items]
Common stock shares				728,814
Common stock option exercise				750,000
common stock withheld with exercise				21,186
Option Five [Member]
Stockholders’ Deficit (Details) [Line Items]
Common stock shares				400,158
Common stock option exercise				409,090
common stock withheld with exercise				8,932
Option Six [Member]
Stockholders’ Deficit (Details) [Line Items]
Common stock shares				731,109
Common stock option exercise				750,000
common stock withheld with exercise				18,891
Preferred Stock [Member]
Stockholders’ Deficit (Details) [Line Items]
Liquidation preference				101.00%

Stockholders_ Deficit (Detail_2

Stockholders’ Deficit (Details) - Schedule of stock options - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of stock options [Abstract]
Shares Outstanding, Beginning Balance	32,000,000	32,900,000
Weighted Average Exercise Price Outstanding, Beginning Balance	$ 0.1419	$ 0.1428
Weighted Average Contractual Term Outstanding, Beginning Balance		6 years 7 months 6 days
Intrinsic Value Outstanding, Beginning Balance	$ 6,054,000	$ 4,731,000
Shares, Granted	1,915,000
Weighted Average Exercise Price, Granted	$ 0.7806
Shares, Exercised	(4,500,000)	(900,000)
Weighted Average Exercise Price, Exercised	$ 0.0856	$ 0.07
Shares, Forfeited or expired	(1,000,000)
Weighted Average Exercise Price, Forfeited or expired	$ 0.37
Shares Outstanding, Ending Balance	28,415,000	32,000,000
Weighted Average Exercise Price Outstanding, Ending Balance	$ 0.1859	$ 0.1419
Weighted Average Contractual Term Outstanding, Ending Balance	5 years 10 months 2 days	5 years 7 months 6 days
Intrinsic Value Outstanding, Ending Balance	$ 60,640,900	$ 6,054,000
Shares Outstanding and Exercisable, Ending Balance	23,128,888
Weighted Average Exercise Price Outstanding and Exercisable, Ending Balance	$ 0.1291
Weighted Average Contractual Term Outstanding and Exercisable, Ending Balance	5 years 10 months 2 days
Intrinsic Value Outstanding and Exercisable, Ending Balance	$ 50,673,665

Stockholders_ Deficit (Detail_3

Stockholders’ Deficit (Details) - Schedule of black-scholes- merton option-pricing model applying the assumptions - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Fair Value of Option [Member]
Stockholders’ Deficit (Details) - Schedule of black-scholes- merton option-pricing model applying the assumptions [Line Items]
Expected life (years)
Dividend yield	0.00%
Expected volatility
Risk free interest rates
Fair Value of Warrant [Member]
Stockholders’ Deficit (Details) - Schedule of black-scholes- merton option-pricing model applying the assumptions [Line Items]
Expected life (years)		1 year
Dividend yield		0.00%
Expected volatility		125.19%
Risk free interest rates		0.14%
Weighted average fair value of warrants at grant date (in Dollars per share)		$ 0.308
Minimum [Member] | Fair Value of Option [Member]
Stockholders’ Deficit (Details) - Schedule of black-scholes- merton option-pricing model applying the assumptions [Line Items]
Expected life (years)	2 years
Expected volatility	128.00%
Risk free interest rates	5.00%
Maximum [Member] | Fair Value of Option [Member]
Stockholders’ Deficit (Details) - Schedule of black-scholes- merton option-pricing model applying the assumptions [Line Items]
Expected life (years)	3 years
Expected volatility	130.00%
Risk free interest rates	7.00%

Stockholders_ Deficit (Detail_4

Stockholders’ Deficit (Details) - Schedule of fair value of restricted stock and restricted stock units - Restricted Stock Outstanding [Member] - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Stockholders’ Deficit (Details) - Schedule of fair value of restricted stock and restricted stock units [Line Items]
Shares, Outstanding beginning balance	75,000
Shares, Granted – restricted stock units and awards	140,000	75
Weighted Average Fair Value per Share at Grant Date, Granted – performance based stock units (in Dollars per share)	$ 0.61	$ 0.35
Shares, Granted – performance based stock units
Weighted Average Fair Value per Share at Grant Date, Granted – performance based stock units (in Dollars per share)
Shares, Canceled
Weighted Average Fair Value per Share at Grant Date, Canceled (in Dollars per share)
Shares, Vested and converted to shares
Weighted Average Fair Value per Share at Grant Date, Vested and converted to shares (in Dollars per share)
Shares, Outstanding ending balance	215,000	75,000
Weighted Average Fair Value per Share at Grant Date, Outstanding ending balance (in Dollars per share)	$ 0.52	$ 0.35

Stockholders_ Deficit (Detail_5

Stockholders’ Deficit (Details) - Schedule of unrecognized stock-based compensation related to unvested restricted stock, net of estimated forfeitures - Warrant Activity [Member] - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Stockholders’ Deficit (Details) - Schedule of unrecognized stock-based compensation related to unvested restricted stock, net of estimated forfeitures [Line Items]
Shares Outstanding, Beginning Balance	3,550,000	3,675,000
Weighted Average Exercise Price Outstanding, Beginning Balance		$ 0.0632
Weighted Average Remaining Contractual Term (years) Outstanding, Beginning Balance		6 years 11 months 15 days
Shares, Granted		50,000
Weighted Average Exercise Price, Granted		$ 0.05
Weighted Average Remaining Contractual Term (years), Granted
Shares, Exercised	(1,650,000)	(175,000)
Weighted Average Exercise Price, Exercised	$ 0.0652	$ 0.07
Shares, Forfeited or expired	(125,000)
Weighted Average Exercise Price, Forfeited or expired	$ 0.0599
Shares Outstanding, Ending Balance	1,775,000	3,550,000
Weighted Average Exercise Price, Ending Balance	$ 0.0599	$ 0.0627
Weighted Average Remaining Contractual Term (years), Ending Balance	7 years 5 months 4 days	6 years 2 months 1 day
Shares, Outstanding and exercisable	1,775,000
Weighted Average Exercise Price, Outstanding and exercisable	$ 0.0599
Weighted Average Remaining Contractual Term (years), Outstanding and exercisable	7 years 5 months 4 days

Stockholders_ Deficit (Detail_6

Stockholders’ Deficit (Details) - Schedule of range exercise prices warrants outstanding and exercisable	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices | $ / shares	$ 1,775,000
Warrants Outstanding Shares Outstanding | shares	7.43
Warrants Outstanding, Weighted Avg. Remaining Contractual Life in Years	21 days
Warrants Outstanding, Weighted Avg. Exercise Price | $ / shares	$ 1,775,000
Warrants Exercisable, Shares Exercisable | shares	0.0599
$0.05 - $0.07 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices | $ / shares	$ 1,775,000
Warrants Outstanding Shares Outstanding | shares	7.43
Warrants Outstanding, Weighted Avg. Remaining Contractual Life in Years	21 days
Warrants Outstanding, Weighted Avg. Exercise Price | $ / shares	$ 1,775,000
Warrants Exercisable, Shares Exercisable | shares	0.0599

Commitments and Contingencies_2

Commitments and Contingencies (Details)	1 Months Ended	12 Months Ended
	Mar. 31, 2021USD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)
Commitments and Contingencies (Details) [Line Items]
Rent expenses		$ 155,000	$ 49,000
Expiry date	Apr. 30, 2026
Future minimum lease payments		$ 112,000
Description of preliminary injunction		As previously reported, on July 3, 2018, we commenced a lawsuit in the Court of Chancery of the State of Delaware against the company’s former director and principal executive officer George Farley (“Farley”) and AnneMarieCo LLC (“AMC”). The parties settled the lawsuit via a written settlement agreement dated September 24, 2020. Under the agreement, 20,000,000 of the 25,000,000 shares originally issued to Farley (20,000,000 of which were transferred to AMC) were invalidated, the remaining 5,000,000 shares being deemed valid under Section 205 of the Delaware General Corporation Law. The agreement calls for the company to repurchase the remaining 5,000,000 shares at a price of $0.30 per share for an aggregate purchase price of $1,500,000. The agreement also provided for the release and return to the company of funds in the amount of $582,377.26, plus interest, securing the bond posted by the company in connection with the preliminary injunction issued in the litigation. The agreement also contains standard mutual general release and confidentiality provisions. Approximately, $206,000 accrued compensation was forgone as per settlement agreement was shown as gain on settlement. In a related matter, on February 8, 2019, the company filed a complaint against Stein Riso Mantel McDonough, LLP (“Stein Riso”), its former counsel, in the United States District Court for the Southern District of New York. The parties settled the lawsuit via a written settlement agreement dated October 2, 2020. Pursuant to the agreement, Stein Riso paid the company three million dollars ($3,000,000) and returned to the company ten million (10,000,000) shares of the company’s common stock, par value $0.001 per share. Stein Riso entered into the Settlement Agreement without any admission of liability. The parties filed a Stipulation of Dismissal with Prejudice as to all claims asserted or which could have been asserted in the lawsuit. The agreement also contains standard mutual general release and confidentiality provisions.
Square Food Laboratory [Member]
Commitments and Contingencies (Details) [Line Items]
Lease square foot	13,000
Minimum lease payment sale lease back transactions within one year	$ 6.7626
Minimum lease payment sale lease back transactions within two year	9.2009
Minimum lease payment sale leaseback transactions within three years	11.4806
Minimum lease payment sale leaseback transactions, within four years	13.174
Minimum lease payment sale leaseback transactions within five years	$ 14.9306

Commitments and Contingencies_3

Commitments and Contingencies (Details) - Schedule of future minimum lease payments	Dec. 31, 2021USD ($)
Schedule of future minimum lease payments [Abstract]
2022	$ 112,141
2023	143,325
2024	168,577
2025	191,779
Thereafter	66,536
Total undiscounted lease payments	682,358
Present value discount, less interest	98,942
Lease Liability	$ 583,416

Income Taxes (Details)

Income Taxes (Details)	12 Months Ended
	Dec. 31, 2021USD ($)
Income Taxes (Details) [Line Items]
Change in valuation allowance	$ 1,163,011
Federal operating loss carryforward	67,200,000
Arizona operating loss carryforward	9,600,000
Pre-USHG merger cumulative unused tax credits	$ 244,000
Income taxes description	the $67.2 million, of Federal net operating loss carryforwards, $57.8 begin to expire in 2021. The remaining balance of $9.4 million is limited in annual usage of 80% of current years taxable income but do not have an expiration. Arizona net operating loss carryforwards began to expire in 2021. In addition, there are federal net operating loss carryforwards of approximately $27.0 million from USHG related to pre-merger losses. We also have pre-merger federal capital loss carryforwards of approximately $520,000.
Minimum [Member]
Income Taxes (Details) [Line Items]
Federal research and development tax credits	$ 239,000
Maximum [Member]
Income Taxes (Details) [Line Items]
Federal research and development tax credits	$ 340,000

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedue of deferred tax assets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Deferred Tax Assets
Accrued Compensation	$ 1,895,848	$ 1,380,954.94
Fixed assets and intangibles	(114,167)	(70,473.82)
Net Operating Loss Carryforwards and Credits	15,070,176	14,378,365
Total Deferred Tax Assets	16,851,857	15,688,846
Valuation allowance	(16,851,857)	(15,688,846)
Net deferred tax / (liabilities)

Income Taxes (Details) - Sche_2

Income Taxes (Details) - Schedule of federal income tax and effective income tax - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of federal income tax and effective income tax [Abstract]
Taxes calculated at federal rate	$ (1,139,345)	$ (634,101)
Taxes calculated at federal rate, percentage	21.00%	21.00%
State income tax, net of federal benefit	$ (195,688)	$ (90,903)
State income tax, net of federal benefit, percentage	3.60%	3.80%
Change in Valuation Allowance	$ 1,163,011	$ 463,091
Change in Valuation Allowance, percentage	(21.40%)	(21.70%)
Expiration of tax attributes	$ 139,331	$ 161,254
Expiration of tax attributes, percentage	(2.60%)	(3.10%)
Prior period adjustment	$ 48,152	$ (49,105)
Prior period adjustment, percentage	(0.90%)	0.00%
Permanent Items	$ (15,460)	$ 149,763
Permanent Items, percentage	0.30%	0.00%
Provision (benefit) for taxes	$ 0	$ 0
Provision (benefit) for taxes, percentage	0.00%	0.00%

Income Taxes (Details) - Sche_3

Income Taxes (Details) - Schedule of unrecognized tax benefits attributable to losses and minimum tax credit carryforwards - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 30, 2020
Schedule of unrecognized tax benefits attributable to losses and minimum tax credit carryforwards [Abstract]
Balance, Beginning	$ 9,635,824	$ 9,635,824
Additions related to prior year tax positions
Reductions related to prior year tax positions and settlements
Additions related to current year tax positions
Balance, Ending	$ 9,635,824

Subsequent Event (Details)

Subsequent Event (Details)	12 Months Ended
	Dec. 31, 2021USD ($)
Subsequent Event (Details) [Line Items]
Subsequent events, description	In January 2022, we issued two options totaling 1,390,000 shares, each with a life of 10 years and an exercise price of $2.40. Subsequent to year end, the Company issued 130,416 shares of common stock in relation to a 2019 compensation agreement.
Directors and Officers insurance premiums	$ 175,434.65
Directors and Officers Insurance Premiums [Member]
Subsequent Event (Details) [Line Items]
Directors and Officers insurance premiums	$ 175,434.65